PD-L1 (CD274) promoter hypomethylation predicts immunotherapy response in metastatic urothelial carcinoma

PD-L1 status assessed by immunohistochemistry (IHC) has failed to reliably predict outcomes for patients with metastatic urothelial carcinoma (mUC) on immune checkpoint blockade (ICB). PD-L1 promoter methylation is an epigenetic mechanism that has been shown to regulate PD-L1 mRNA expression in vari...

Descripción completa

Detalles Bibliográficos
Autores principales: Klümper, Niklas, Wüst, Lennert, Saal, Jonas, Ralser, Damian J., Zarbl, Romina, Jarczyk, Jonas, Breyer, Johannes, Sikic, Danijel, Wullich, Bernd, Bolenz, Christian, Roghmann, Florian, Hölzel, Michael, Ritter, Manuel, Strieth, Sebastian, Hartmann, Arndt, Erben, Philipp, Wirtz, Ralph M., Landsberg, Jennifer, Dietrich, Dimo, Eckstein, Markus
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2023
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10588513/
https://www.ncbi.nlm.nih.gov/pubmed/37868689
http://dx.doi.org/10.1080/2162402X.2023.2267744

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10588513/
https://www.ncbi.nlm.nih.gov/pubmed/37868689
http://dx.doi.org/10.1080/2162402X.2023.2267744

Ejemplares similares